ClinicalTrials.gg
CompletedNCT04570657FRONTIER-3Updated Jan 30, 2024Results posted

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

A Phase 2 interventional study of MEDI3506 and Placebo in Asthma, sponsored by AstraZeneca. Completed at 65 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
104th of 248
250 · median 175
Started
2020
with 6 others
Phase 2
50 of 359
2 open now
Registered
269th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 104th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2020, is one of 50 in phase 2, and was the 269th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants with uncontrolled moderate to severe asthma on standard of care (SOC). Up to approximately 80 sites globally will participate in this study.

Approximately 228 participants will be randomized to 3 treatment groups in a 1:1:1 ratio to receive MEDI3506 dose 1, MEDI3506 dose 2, or placebo.

03

Conditions studied

  • Asthma

Keywords

  • MEDI3506
  • lung function
  • IL-33
  • inflammation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to \< 65 years of age
  • Physician-diagnosed asthma of early onset, defined as development of asthma before the age of 25 years.
  • History of ≥ 1 asthma exacerbation in previous 24 months
  • Treated with medium to high dose ICS defined as total daily dose of > 250 g fluticasone dry powder or equivalent, for at least 12 months and on a stable dose for ≥ 3 months.
  • Stable LABA therapy for ≥ 3 months.
  • An ACQ-6 score ≥ 1.5.
  • Morning pre-BD ≥ 40% predicted normal and > 1 L.
  • Morning pre-BD FEV1 \< 85% predicted normal.
  • Participants with documented evidence of asthma as demonstrated by either:
  • BD reversibility, within 12 months, or at screening, or
  • Positive methacholine challenge test within 12 months.
  • Bodyweight ≥ 40 kg and \< 40 kg/m2.
  • For female participants, a negative pregnancy test.
  • Abide by requirements for males and females
  • Provide

Exclusion criteria

EXCLUSION CRITERIA

  • Participants with a positive diagnostic nucleic acid test for SARS-CoV-2.
  • Participants with a significant COVID-19 illness within 6 months of enrolment:
  • Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for , , or .
  • Evidence of active or latent TB:
  • An \< 45% measured by echocardiogram during screening.
  • A family history of heart failure.
  • Current smokers or recent ex-smokers i.e., have quit e cigarettes or other inhaled tobacco products ≤ 6 months prior to SV1.
  • Ex-smokers with a total smoking history of > 10 pack years.
  • As judged by the investigator, any evidence of any active medical or psychiatric condition or other reason (prior to randomisation) that in the investigator's opinion makes it undesirable for the participant to participate in the study.
  • Any pulmonary disease other than asthma.
  • Any other clinically relevant abnormal findings on physical examination or laboratory testing, that in the opinion of the investigator or medical monitor might compromise the safety of the participant in the study or interfere with evaluation of the study intervention.
  • A known history of severe reaction to any medication including biologic agents or human gamma globulin therapy.
  • History of, or a reason to believe, a participant has a history of, drug or alcohol abuse within the past 2 years.
  • Current diagnosis of cancer.
  • History of cancer, except if treated with apparent success with curative therapy (response duration of > 5 years).
  • History of bone marrow transplant.
  • A helminth parasitic infection diagnosed within 6 months prior to SV4 (randomisation) that has not been treated, or has not responded to SOC therapy.
  • An asthma exacerbation within 8 weeks.
  • Receiving any prohibited concomitant medications or therapies as specified in the protocol:

Known history of allergy or reaction to any component of the study intervention formulation, including hereditary fructose intolerance.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    MEDI3506 Dose 1

    Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506

    Biological: MEDI3506

  • Experimental
    MEDI3506 Dose 2

    Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506

    Biological: MEDI3506

  • Placebo comparator
    Placebo

    Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.

    Drug: Placebo

Interventions

  • BiologicalMEDI3506

    Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2

  • DrugPlacebo

    Participants will receive multiple doses of placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic

    In-clinic spirometry measurements were taken prior to the administration of bronchodilators. Baseline was the last measurement prior to first injection of investigational product (IP). The least squares (LS) means, LS mean differences and 80% confidence intervals (CIs), and one-sided p-value results were based on a mixed model repeated measures (MMRM). The model included fixed effects for baseline, background medication, geographic region, baseline inhaled corticosteroids (ICS) total daily dose, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements.

    Time frame: Baseline and week 16

Secondary outcomes

  1. Change From Baseline to Weeks 8 and 16 in Post-bronchodilator (Post-BD) FEV1 as Measured in the Study Clinic

    In-clinic spirometry measurements were taken following the use of bronchodilators. Bronchodilatation was induced using albuterol (90 µg metered dose), salbutamol (100 µg metered dose), or levalbuterol (45 µg metered dose), and measurements were taken after up to a maximum of 4 inhalations. Baseline was the last measurement prior to first injection of IP. The LS means, LS mean differences and 80% CIs, and one-sided p-value results were based on MMRM. The model included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements.

    Time frame: Baseline and weeks 8 and 16

  2. Serum Concentrations of Tozorakimab

    Tozorakimab serum concentrations were measured using a validated assay method.

    Time frame: Pharmacokinetic (PK) samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, 20, and 24

  3. Number of Participants With Anti-drug Antibodies (ADAs)

    ADA prevalence is the number of participants ADA positive (ADA+) at baseline and/or post-baseline. Treatment-emergent ADA+ (TE-ADA +) positive is defined as being either of treatment-induced ADA+ (ADA negative \[ADA-\] at baseline and at least one post-baseline ADA+) and treatment-boosted ADA+ (ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point). Treatment-emergent ADA- (TE-ADA-) is defined as ADA+ but not fulfilling the definition of TE-ADA+. ADA persistently positive is defined as ADA- at baseline and ADA+ at ≥ 2 post-baseline assessment with ≥ 16 weeks between first and last positive assessments, or ADA+ at the last post-baseline assessment. ADA transiently positive is defined as ADA- at baseline, having at least one post-baseline ADA+ assessment and not fulfilling the conditions of ADA persistently positive. Baseline is defined as the last ADA assessment prior to first injection of IP.

    Time frame: Blood samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, and 24

  4. Change From Baseline to Week 16 in the Asthma Control Questionnaire-6 (ACQ-6) Score

    In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between \>0.75 and \<1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. Results were based on an MMRM which included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. A negative change from baseline indicates an improvement in asthma control.

    Time frame: Baseline and week 16

  5. Number of Participants With a Decrease in ACQ-6 Score ≥ 0.5 From Baseline to Week 16

    In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between \>0.75 and \<1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. A decrease in ACQ-6 score baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful.

    Time frame: Baseline and week 16

  6. Number of Participants Achieving ACQ-6 Well Controlled Status at Week 16

    In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between \>0.75 and \<1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma.

    Time frame: Baseline and week 16

  7. Change From Baseline to Week 16 in St George's Respiratory Questionnaire (SGRQ) Domain and Total Scores

    The SGRQ is a 50-item patient-reported outcome instrument to measure the health status of participants with airway obstruction diseases, giving a total score and 3 domain scores (symptoms, activity, and impacts). The total score is expressed as a percentage of overall impairment, with 100 representing the worst possible health status and 0 the best possible health status. Each domain score ranges from 0 to 100, with higher scores indicating greater impairment. A negative change from baseline indicates an improvement in impairments. Results were based on an MMRM which included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements.

    Time frame: Baseline and week 16

  8. Number of Participants With a Decrease in SGRQ Total Score of ≥ 4 Points From Baseline to Week 16

    The SGRQ is a 50-item patient-reported outcome instrument to measure the health status of participants with airway obstruction diseases, giving a total score and 3 domain scores (symptoms, activity, and impacts). The total score is expressed as a percentage of overall impairment, with 100 representing the worst possible health status and 0 the best possible health status. A decrease in the SGRQ total score indicates an improvement in overall impairment.

    Time frame: Baseline and week 16

  9. Number of Participants With at Least One Asthma CompEx Event From Baseline to Week 16

    Asthma CompEx is a combination of exacerbations of asthma and diary events (i.e., a combination of electronic diary \[eDiary\] variables). eDiary events are defined by criteria using morning/evening diary variables of PEF, symptoms, and use of rescue medication. A participant was considered to have a CompEx event if they had one or both of an asthma exacerbation or diary event. For participants who did not experience an on-treatment CompEx event, date of censoring was the minimum between the date of last dose + 28 days, and the last day of eDiary recording during the on-treatment period.

    Time frame: Baseline to week 16

  10. Asthma CompEx Annualised Event Rate

    The annualised rate of asthma CompEx events was calculated as the total number of asthma CompEx events / (date of last dose of IP + 28 - date of first dose of IP - recovery time + 1) / 365.25. The rates, rate ratios, and one-sided p-values were estimated from a negative binomial regression, with the log(follow up time) included as an offset term. The dependent variable will be the number of CompEx events during the on-treatment period (i.e., from baseline to last dose date +28 days), and the model will include treatment group, background medication, geographic region and baseline ICS total daily dose as covariates.

    Time frame: Baseline to week 16

  11. Percent Change From Baseline to Week 16 in Concentration of Fractional Exhaled Nitric Oxide (FeNO) in Exhaled Breath

    A standardised single-breath FeNO test was performed to evaluate airway inflammation. Results were based on MMRM on log-transformed change from baseline. Log-transformed change from baseline is calculated as the visit value in log minus the baseline value in log. The results from the model were then back transformed. The model included fixed effects for baseline (in log), background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within subject were considered as repeated measurements.

    Time frame: Baseline and week 16

Other outcomes

  1. Change From Baseline to Week 16 in Pre-BD FEV1 as Measured in the Study Clinic: Analysis Per Number of Exacerbations in Last 12 Months

    In-clinic spirometry measurements were taken prior to the administration of bronchodilators. Baseline was the last measurement prior to first injection of IP. The LS means, LS mean differences and 80% CIs, and one-sided p-value results were based on MMRM. The model included fixed effects for baseline, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. Analysis is presented by the number of asthma exacerbations experienced within the 12 months prior to baseline (1 or ≥ 2 exacerbations in the previous 12 months).

    Time frame: Baseline and week 16

  2. Eosinophil Count

    The eosinophil count at baseline and week 16 are presented. Baseline was defined as the last measurement prior to first injection of IP.

    Time frame: Baseline and Week 16

07

Results

Posted Jan 30, 2024
Limitations and caveats
15 participants enrolled at 1 study centre were excluded from the final analysis due to inability to confirm the validity of the data reported by the site. The exclusion of data from this site did not change the interpretation of the primary endpoint, or results in a significant change to the interpretation of any other endpoint.

Participant flow

Participants were enrolled and randomised in 52 study centres in 7 countries including Argentina, Germany, Hungary, Poland, South Africa, the United Kingdom, and the United States from 17 September 2020. The last participant completed their last study visit on 06 February 2023.

Participant flow — Overall Study
MilestoneTozorakimab Dose ATozorakimab Dose BPlacebo
Started777781
Intent to treat (itt) population777781
As-treated population777781
Pharmacokinetic (pk) population75770
Completed767477
Not completed134
Withdrew: Adverse event001
Withdrew: Lost to follow-up001
Withdrew: Physician decision010
Withdrew: Withdrawal by subject122

Outcome measures

PrimaryChange From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic

In-clinic spirometry measurements were taken prior to the administration of bronchodilators. Baseline was the last measurement prior to first injection of investigational product (IP). The least squares (LS) means, LS mean differences and 80% confidence intervals (CIs), and one-sided p-value results were based on a mixed model repeated measures (MMRM). The model included fixed effects for baseline, background medication, geographic region, baseline inhaled corticosteroids (ICS) total daily dose, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · litres
Change From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic
litresTozorakimab Dose ATozorakimab Dose BPlacebo
Change From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic0.148 ± 0.0470.116 ± 0.0480.112 ± 0.046
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.267 (One-sided p-value) · Ls mean difference: 0.036 · 80% CI -0.038 to 0.111Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.473 (One-sided p-value) · Ls mean difference: 0.004 · 80% CI -0.071 to 0.079Tozorakimab Dose B - Placebo
SecondaryChange From Baseline to Weeks 8 and 16 in Post-bronchodilator (Post-BD) FEV1 as Measured in the Study Clinic

In-clinic spirometry measurements were taken following the use of bronchodilators. Bronchodilatation was induced using albuterol (90 µg metered dose), salbutamol (100 µg metered dose), or levalbuterol (45 µg metered dose), and measurements were taken after up to a maximum of 4 inhalations. Baseline was the last measurement prior to first injection of IP. The LS means, LS mean differences and 80% CIs, and one-sided p-value results were based on MMRM. The model included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements.

Time frame:
Baseline and weeks 8 and 16
Reported as:
Least squares mean · litres
Change From Baseline to Weeks 8 and 16 in Post-bronchodilator (Post-BD) FEV1 as Measured in the Study Clinic
litresTozorakimab Dose ATozorakimab Dose BPlacebo
Week 8-0.062 ± 0.0670.008 ± 0.068-0.050 ± 0.060
Week 16-0.064 ± 0.067-0.050 ± 0.068-0.026 ± 0.060
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.437 (One-sided p-value) · Ls mean difference: -0.012 · 80% CI -0.110 to 0.086Week 8: Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.221 (One-sided p-value) · Ls mean difference: 0.059 · 80% CI -0.039 to 0.157Week 8: Tozorakimab Dose B - Placebo
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.308 (One-sided p-value) · Ls mean difference: -0.038 · 80% CI -0.136 to 0.060Week 16: Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.372 (One-sided p-value) · Ls mean difference: -0.025 · 80% CI -0.122 to 0.072Week 16: Tozorakimab Dose B - Placebo
SecondarySerum Concentrations of Tozorakimab

Tozorakimab serum concentrations were measured using a validated assay method.

Time frame:
Pharmacokinetic (PK) samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, 20, and 24
Reported as:
Geometric mean · µg/L
Serum Concentrations of Tozorakimab
µg/LTozorakimab Dose ATozorakimab Dose B
Pre-doseNA ± NANA ± NA
Week 18939.24 ± 367.3118374.15 ± 239.89
Week 42165.82 ± 180.174102.04 ± 168.60
Week 82680.07 ± 113.594476.11 ± 109.27
Week 122673.94 ± 121.084646.57 ± 153.62
Week 162742.93 ± 128.835007.93 ± 117.76
Week 20356.56 ± 177.25761.75 ± 152.78
Week 2480.36 ± 170.34146.67 ± 214.16
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs)

ADA prevalence is the number of participants ADA positive (ADA+) at baseline and/or post-baseline. Treatment-emergent ADA+ (TE-ADA +) positive is defined as being either of treatment-induced ADA+ (ADA negative \[ADA-\] at baseline and at least one post-baseline ADA+) and treatment-boosted ADA+ (ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point). Treatment-emergent ADA- (TE-ADA-) is defined as ADA+ but not fulfilling the definition of TE-ADA+. ADA persistently positive is defined as ADA- at baseline and ADA+ at ≥ 2 post-baseline assessment with ≥ 16 weeks between first and last positive assessments, or ADA+ at the last post-baseline assessment. ADA transiently positive is defined as ADA- at baseline, having at least one post-baseline ADA+ assessment and not fulfilling the conditions of ADA persistently positive. Baseline is defined as the last ADA assessment prior to first injection of IP.

Time frame:
Blood samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, and 24
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs)
ParticipantsTozorakimab Dose ATozorakimab Dose BPlacebo
ADA prevalence331
TE-ADA+321
Treatment-induced ADA+321
TE-ADA-010
Both baseline and post-baseline positive010
ADA persistently positive310
ADA transiently positive011
SecondaryChange From Baseline to Week 16 in the Asthma Control Questionnaire-6 (ACQ-6) Score

In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between \>0.75 and \<1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. Results were based on an MMRM which included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. A negative change from baseline indicates an improvement in asthma control.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 16 in the Asthma Control Questionnaire-6 (ACQ-6) Score
score on a scaleTozorakimab Dose ATozorakimab Dose BPlacebo
Change From Baseline to Week 16 in the Asthma Control Questionnaire-6 (ACQ-6) Score-0.925 ± 0.117-0.942 ± 0.117-0.895 ± 0.112
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.416 (One-sided p-value) · Ls mean difference: -0.030 · 80% CI -0.215 to 0.154Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.371 (One-sided p-value) · Ls mean difference: -0.047 · 80% CI -0.231 to 0.137Tozorakimab Dose B - Placebo
SecondaryNumber of Participants With a Decrease in ACQ-6 Score ≥ 0.5 From Baseline to Week 16

In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between \>0.75 and \<1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. A decrease in ACQ-6 score baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful.

Time frame:
Baseline and week 16
Reported as:
Count of participants · Participants
Number of Participants With a Decrease in ACQ-6 Score ≥ 0.5 From Baseline to Week 16
ParticipantsTozorakimab Dose ATozorakimab Dose BPlacebo
Number of Participants With a Decrease in ACQ-6 Score ≥ 0.5 From Baseline to Week 16535653
Statistical analysis
  • Tozorakimab Dose A vs Placebo · Chi-squared · p = 0.612 · Odds ratio (or): 1.20 · 80% CI 0.76 to 1.90
  • Tozorakimab Dose B vs Placebo · Chi-squared · p = 0.348 · Odds ratio (or): 1.41 · 80% CI 0.88 to 2.25
SecondaryNumber of Participants Achieving ACQ-6 Well Controlled Status at Week 16

In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between \>0.75 and \<1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma.

Time frame:
Baseline and week 16
Reported as:
Count of participants · Participants
Number of Participants Achieving ACQ-6 Well Controlled Status at Week 16
ParticipantsTozorakimab Dose ATozorakimab Dose BPlacebo
Number of Participants Achieving ACQ-6 Well Controlled Status at Week 16171821
Statistical analysis
  • Tozorakimab Dose A vs Placebo · Chi-squared · p = 0.575 · Odds ratio (or): 0.81 · 80% CI 0.50 to 1.31
  • Tozorakimab Dose B vs Placebo · Chi-squared · p = 0.679 · Odds ratio (or): 0.86 · 80% CI 0.53 to 1.38
SecondaryChange From Baseline to Week 16 in St George's Respiratory Questionnaire (SGRQ) Domain and Total Scores

The SGRQ is a 50-item patient-reported outcome instrument to measure the health status of participants with airway obstruction diseases, giving a total score and 3 domain scores (symptoms, activity, and impacts). The total score is expressed as a percentage of overall impairment, with 100 representing the worst possible health status and 0 the best possible health status. Each domain score ranges from 0 to 100, with higher scores indicating greater impairment. A negative change from baseline indicates an improvement in impairments. Results were based on an MMRM which included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 16 in St George's Respiratory Questionnaire (SGRQ) Domain and Total Scores
score on a scaleTozorakimab Dose ATozorakimab Dose BPlacebo
SGRQ Activity Total Score-10.340 ± 2.477-11.706 ± 2.507-10.342 ± 2.390
SGRQ Impacts Total Score-8.237 ± 1.750-8.509 ± 1.774-6.816 ± 1.689
SGRQ Symptoms Total Score-15.290 ± 2.828-19.130 ± 2.873-15.981 ± 2.726
SGRQ Total Score-10.133 ± 1.815-11.366 ± 1.838-9.470 ± 1.750
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.500 (One-sided p-value) · Ls mean difference: 0.002 · 80% CI -3.825 to 3.828SGRQ Activity Total Score: Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.324 (One-sided p-value) · Ls mean difference: -1.364 · 80% CI -5.198 to 2.470SGRQ Activity Total Score: Tozorakimab Dose B - Placebo
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.248 (One-sided p-value) · Ls mean difference: -1.421 · 80% CI -4.103 to 1.260SGRQ Impacts Total Score: Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.210 (One-sided p-value) · Ls mean difference: -1.694 · 80% CI -4.383 to 0.996SGRQ Impacts Total Score: Tozorakimab Dose B - Placebo
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.420 (One-sided p-value) · Ls mean difference: 0.691 · 80% CI -3.715 to 5.096SGRQ Symptoms Total Score: Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.181 (One-sided p-value) · Ls mean difference: -3.150 · 80% CI -7.579 to 1.280SGRQ Symptoms Total Score: Tozorakimab Dose B - Placebo
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.380 (One-sided p-value) · Ls mean difference: -0.663 · 80% CI -3.454 to 2.129SGRQ Total Score: Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.192 (One-sided p-value) · Ls mean difference: -1.896 · 80% CI -4.694 to 0.903SGRQ Total Score: Tozorakimab Dose B - Placebo
SecondaryNumber of Participants With a Decrease in SGRQ Total Score of ≥ 4 Points From Baseline to Week 16

The SGRQ is a 50-item patient-reported outcome instrument to measure the health status of participants with airway obstruction diseases, giving a total score and 3 domain scores (symptoms, activity, and impacts). The total score is expressed as a percentage of overall impairment, with 100 representing the worst possible health status and 0 the best possible health status. A decrease in the SGRQ total score indicates an improvement in overall impairment.

Time frame:
Baseline and week 16
Reported as:
Count of participants · Participants
Number of Participants With a Decrease in SGRQ Total Score of ≥ 4 Points From Baseline to Week 16
ParticipantsTozorakimab Dose ATozorakimab Dose BPlacebo
Number of Participants With a Decrease in SGRQ Total Score of ≥ 4 Points From Baseline to Week 16505354
Statistical analysis
  • Tozorakimab Dose A vs Placebo · Chi-squared · p = 0.828 · Odds ratio (or): 0.93 · 80% CI 0.59 to 1.46
  • Tozorakimab Dose B vs Placebo · Chi-squared · p = 0.840 · Odds ratio (or): 1.07 · 80% CI 0.68 to 1.70
SecondaryNumber of Participants With at Least One Asthma CompEx Event From Baseline to Week 16

Asthma CompEx is a combination of exacerbations of asthma and diary events (i.e., a combination of electronic diary \[eDiary\] variables). eDiary events are defined by criteria using morning/evening diary variables of PEF, symptoms, and use of rescue medication. A participant was considered to have a CompEx event if they had one or both of an asthma exacerbation or diary event. For participants who did not experience an on-treatment CompEx event, date of censoring was the minimum between the date of last dose + 28 days, and the last day of eDiary recording during the on-treatment period.

Time frame:
Baseline to week 16
Reported as:
Count of participants · Participants
Number of Participants With at Least One Asthma CompEx Event From Baseline to Week 16
ParticipantsTozorakimab Dose ATozorakimab Dose BPlacebo
Number of Participants With at Least One Asthma CompEx Event From Baseline to Week 16191515
Statistical analysis
  • Tozorakimab Dose A vs Placebo · Regression, Cox · p = 0.239 (One-sided p-value) · Hazard ratio (hr): 1.3 · 80% CI 0.8 to 2.0Cox regression model with treatment group, background medication, geographic region, and ICS total daily dose as covariates.
  • Tozorakimab Dose B vs Placebo · Regression, Cox · p = 0.461 (One-sided p-value) · Hazard ratio (hr): 1.0 · 80% CI 0.6 to 1.7Cox regression model with treatment group, background medication, geographic region, and ICS total daily dose as covariates.
SecondaryAsthma CompEx Annualised Event Rate

The annualised rate of asthma CompEx events was calculated as the total number of asthma CompEx events / (date of last dose of IP + 28 - date of first dose of IP - recovery time + 1) / 365.25. The rates, rate ratios, and one-sided p-values were estimated from a negative binomial regression, with the log(follow up time) included as an offset term. The dependent variable will be the number of CompEx events during the on-treatment period (i.e., from baseline to last dose date +28 days), and the model will include treatment group, background medication, geographic region and baseline ICS total daily dose as covariates.

Time frame:
Baseline to week 16
Reported as:
Number · events per participant-treatment year
Asthma CompEx Annualised Event Rate
events per participant-treatment yearTozorakimab Dose ATozorakimab Dose BPlacebo
Asthma CompEx Annualised Event Rate0.86 (0.58 to 1.28)0.69 (0.44 to 1.07)0.99 (0.68 to 1.44)
Statistical analysis
  • Tozorakimab Dose A vs Placebo · Negative binomial regression · p = 0.346 (One-sided p-value) · Rate ratio: 0.87 · 80% CI 0.56 to 1.36
  • Tozorakimab Dose B vs Placebo · Negative binomial regression · p = 0.166 (One-sided p-value) · Rate ratio: 0.70 · 80% CI 0.43 to 1.12
SecondaryPercent Change From Baseline to Week 16 in Concentration of Fractional Exhaled Nitric Oxide (FeNO) in Exhaled Breath

A standardised single-breath FeNO test was performed to evaluate airway inflammation. Results were based on MMRM on log-transformed change from baseline. Log-transformed change from baseline is calculated as the visit value in log minus the baseline value in log. The results from the model were then back transformed. The model included fixed effects for baseline (in log), background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within subject were considered as repeated measurements.

Time frame:
Baseline and week 16
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline to Week 16 in Concentration of Fractional Exhaled Nitric Oxide (FeNO) in Exhaled Breath
percent changeTozorakimab Dose ATozorakimab Dose BPlacebo
Percent Change From Baseline to Week 16 in Concentration of Fractional Exhaled Nitric Oxide (FeNO) in Exhaled Breath-17.429 (-23.423 to -10.965)-16.500 (-22.548 to -9.981)-5.007 (-11.612 to 2.091)
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.029 (One-sided p-value) · Geometric ls mean ratio: 0.869 · 80% CI 0.791 to 0.956
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.040 (One-sided p-value) · Geometric ls mean ratio: 0.879 · 80% CI 0.800 to 0.966
Other pre-specifiedChange From Baseline to Week 16 in Pre-BD FEV1 as Measured in the Study Clinic: Analysis Per Number of Exacerbations in Last 12 Months

In-clinic spirometry measurements were taken prior to the administration of bronchodilators. Baseline was the last measurement prior to first injection of IP. The LS means, LS mean differences and 80% CIs, and one-sided p-value results were based on MMRM. The model included fixed effects for baseline, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. Analysis is presented by the number of asthma exacerbations experienced within the 12 months prior to baseline (1 or ≥ 2 exacerbations in the previous 12 months).

Time frame:
Baseline and week 16
Reported as:
Least squares mean · litres
Change From Baseline to Week 16 in Pre-BD FEV1 as Measured in the Study Clinic: Analysis Per Number of Exacerbations in Last 12 Months
litresTozorakimab Dose ATozorakimab Dose BPlacebo
1 Exacerbation in Last 12 Months0.188 ± 0.0650.042 ± 0.0700.165 ± 0.062
≥ 2 Exacerbations in Last 12 Months0.059 ± 0.0670.194 ± 0.065-0.018 ± 0.069
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.385 (One-sided p-value; alpha = 0.1) · Ls mean difference: 0.023 · 80% CI -0.078 to 0.124Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.060 (One-sided p-value; alpha = 0.1) · Ls mean difference: -0.123 · 80% CI -0.224 to -0.022Tozorakimab Dose B - Placebo
  • Tozorakimab Dose A vs Placebo · MMRM · p = 0.186 (One-sided p-value; alpha = 0.1) · Ls mean difference: 0.077 · 80% CI -0.034 to 0.187Tozorakimab Dose A - Placebo
  • Tozorakimab Dose B vs Placebo · MMRM · p = 0.007 (One-sided p-value; alpha = 0.1) · Ls mean difference: 0.212 · 80% CI 0.102 to 0.322Tozorakimab Dose B - Placebo
Other pre-specifiedEosinophil Count

The eosinophil count at baseline and week 16 are presented. Baseline was defined as the last measurement prior to first injection of IP.

Time frame:
Baseline and Week 16
Reported as:
Geometric mean · 10^9 cells/L
Eosinophil Count
10^9 cells/LTozorakimab Dose ATozorakimab Dose BPlacebo
Baseline0.187 ± 80.40.200 ± 88.40.178 ± 83.3
Week 160.122 ± 82.90.136 ± 77.60.185 ± 93.2
Statistical analysis
  • Tozorakimab Dose A vs Placebo · MMRM · p = < 0.001 (One-sided p-value) · Geometric ls mean ratio: 0.630 · 80% CI 0.559 to 0.710
  • Tozorakimab Dose B vs Placebo · MMRM · p = < 0.001 (One-sided p-value) · Geometric ls mean ratio: 0.675 · 80% CI 0.599 to 0.760

Adverse events

Collected over Day 1 to Week 24 (up to 24 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tozorakimab Dose A0/77 (0%)1/77 (1.3%)25/77 (32.5%)
Tozorakimab Dose B0/77 (0%)4/77 (5.2%)20/77 (26%)
Placebo0/81 (0%)2/81 (2.5%)20/81 (24.7%)
Most frequent serious events
Most frequent serious events
EventTozorakimab Dose ATozorakimab Dose BPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders0/772/770/81
BronchitisInfections and infestations0/771/770/81
Acid peptic diseaseGastrointestinal disorders0/771/770/81
AstheniaGeneral disorders0/771/770/81
Clavicle fractureInjury, poisoning and procedural complications1/770/770/81
Clostridium difficile colitisInfections and infestations0/770/771/81
Umbilical herniaGastrointestinal disorders0/770/771/81
Most frequent other events
Most frequent other events
EventTozorakimab Dose ATozorakimab Dose BPlacebo
COVID-19Infections and infestations15/7710/7711/81
Injection site erythemaGeneral disorders4/777/772/81
NasopharyngitisInfections and infestations6/775/774/81
Urinary tract infectionInfections and infestations4/772/773/81
Injection site swellingGeneral disorders0/774/771/81
Injection site urticariaGeneral disorders1/774/770/81

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tozorakimab Dose ATozorakimab Dose BPlaceboTotal
Mean42.1 ± 11.9743.1 ± 12.3748.3 ± 10.4144.5 ± 11.87
Sex: Female, Male
Sex: Female, Male(Participants)Tozorakimab Dose ATozorakimab Dose BPlaceboTotal
Female535443150
Male24233885
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tozorakimab Dose ATozorakimab Dose BPlaceboTotal
Hispanic or Latino26243383
Not Hispanic or Latino515348152
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tozorakimab Dose ATozorakimab Dose BPlaceboTotal
Asian0011
Black or African American48719
White716772210
Other2215
08

Study locations

65 sites
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Ames, Iowa 50010-3014, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Toledo, Ohio 43617, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    Buenos Aires, C1121 ABE, Argentina
  • Research Site
    Buenos Aires, C1414AIF, Argentina
  • Research Site
    Caba, C1425BEN, Argentina
  • Research Site
    Cordoba, X5003DCE, Argentina
  • Research Site
    Florencio Varela, 1888, Argentina
  • Research Site
    Florida, B1602DQD, Argentina
  • Research Site
    Godoy Cruz, 5501, Argentina
  • Research Site
    Lanus Este, B1824KAJ, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Mendoza, M5500GHB, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    San Miguel de Tucuman, 4000, Argentina
  • Research Site
    Berlin, 10717, Germany
  • Research Site
    Cottbus, 03050, Germany
  • Research Site
    Frankfurt/Main, 60389, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Koblenz, 56068, Germany
  • Research Site
    Landsberg, 86899, Germany
  • Research Site
    Leipzig, 04357, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Mainz, 55128, Germany
  • Research Site
    Peine, 31224, Germany
  • Research Site
    Schwerin, 19055, Germany
  • Research Site
    Balassagyarmat, 2660, Hungary
  • Research Site
    Budapest, 1033, Hungary
  • Research Site
    Gödöllő, 2100, Hungary
  • Research Site
    Szeged, 6722, Hungary
  • Research Site
    Százhalombatta, 2440, Hungary
  • Research Site
    Białystok, 15-044, Poland
  • Research Site
    Bychawa, 23100, Poland
  • Research Site
    Bydgoszcz, 85-231, Poland
  • Research Site
    Katowice, 40-648, Poland
  • Research Site
    Krakow, 30-033, Poland
  • Research Site
    Lodz, 90-302, Poland
  • Research Site
    Lublin, 20-362, Poland
  • Research Site
    Poznań, 60-214, Poland
  • Research Site
    Tarnów, 33-100, Poland
  • Research Site
    Wroclaw, 54-239, Poland
  • Research Site
    Wrocław, 53-301, Poland
  • Research Site
    Bellville, 7530, South Africa
  • Research Site
    Benoni, 1500, South Africa
  • Research Site
    Bloemfontein, 9301, South Africa
  • Research Site
    Cape Town, 7500, South Africa
  • Research Site
    Cape Town, 7572, South Africa
  • Research Site
    Cape Town, 7700, South Africa
  • Research Site
    Durban, 4001, South Africa
  • Research Site
    Durban, 4091, South Africa
  • Research Site
    Johannesburg, 2113, South Africa
  • Research Site
    Pretoria, 0002, South Africa
  • Research Site
    Welkom, 9460, South Africa
  • Research Site
    Bradford, BD9 6RJ, United Kingdom
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    High Wycombe, HP11 2QW, United Kingdom
  • Research Site
    London, W1T 6AH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2022, 26 months.

Results were first posted in Jan 2024, 1 year 1 month after primary completion.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 26 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Sep 30, 2020
StartActual
Sep 17, 2020
Primary completionActual
Dec 12, 2022
CompletionActual
Feb 6, 2023
Results first posted
Jan 30, 2024
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04570657
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Sep 17, 2020
Primary completion
Dec 12, 2022
Completion
Feb 6, 2023
Results posted
Jan 30, 2024
Last update
Jan 30, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion